Chord Energy Corporation (CHRD)

Elevation Oncology Stock Forecast

Stock Price Forecast

The 12 analysts that cover Elevation Oncology stock have a consensus rating of "Buy" and an average price target of $151.25, which forecasts a 43.54% increase in the stock price over the next year. The lowest target is $112 and the highest is $186.

Price Target: $151.25 (+43.54%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$112	$151.25	$155	$186
Change	+6.29%	+43.54%	+47.10%	+76.52%

Analyst Ratings

The average analyst rating for Elevation Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	4	3	4	4	4	4
Buy	6	6	6	6	6	6
Hold	3	3	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	12	12	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mark Lear Piper Sandler	Piper Sandler	Buy Maintains $159 → $164	Buy	Maintains	$159 → $164	+55.64%	Jul 17, 2025
Hanwen Chang Wells Fargo	Wells Fargo	Buy Maintains $142 → $143	Buy	Maintains	$142 → $143	+35.71%	Jul 15, 2025
Paul Diamond Citigroup	Citigroup	Strong Buy Maintains $120 → $125	Strong Buy	Maintains	$120 → $125	+18.63%	Jul 9, 2025
Mark Lear Piper Sandler	Piper Sandler	Buy Maintains $161 → $159	Buy	Maintains	$161 → $159	+50.90%	Jul 1, 2025
Hanwen Chang Wells Fargo	Wells Fargo	Buy Maintains $158 → $142	Buy	Maintains	$158 → $142	+34.76%	Jun 16, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

4.51B

Decreased by -8.29%

from 4.92B

Revenue Next Year

4.38B

Decreased by -2.86%

from 4.51B

EPS This Year

10.03

Decreased by -37.38%

from 16.02

EPS Next Year

8.93

Decreased by -10.99%

from 10.03

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	901.07M	1.50B	3.42B	3.64B	4.92B	4.51B	4.38B	4.53B
Revenue Growth	-50.44%	66.81%	127.35%	6.42%	35.23%	-8.29%	-2.86%	3.47%
EPS	-13.02	15.48	57.55	23.51	16.02	10.03	8.93	12.04
EPS Growth	-	-	271.83%	-59.14%	-31.86%	-37.38%	-10.99%	34.86%
Forward PE	-	-	-	-	-	10.50	11.80	8.75
No. Analysts	-	-	-	-	-	18	17	11

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	6.1B	6.2B	5.4B
Avg	4.5B	4.4B	4.5B
Low	3.7B	3.4B	3.8B

Revenue Growth

Revenue Growth	2025	2026	2027
High	25.0%	36.5%	23.1%
Avg	-8.3%	-2.9%	3.5%
Low	-25.6%	-23.9%	-13.8%

EPS Forecast

EPS	2025	2026	2027
High	15.28	16.50	21.44
Avg	10.03	8.93	12.04
Low	7.17	4.83	7.06

EPS Growth

EPS Growth	2025	2026	2027
High	-4.7%	64.4%	140.1%
Avg	-37.4%	-11.0%	34.9%
Low	-55.2%	-51.9%	-21.0%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.